2,798 reports of this reaction
2.2% of all ONABOTULINUMTOXINA reports
#8 most reported adverse reaction
MULTIPLE USE OF SINGLE USE PRODUCT is the #8 most commonly reported adverse reaction for ONABOTULINUMTOXINA, manufactured by Allergan, Inc.. There are 2,798 FDA adverse event reports linking ONABOTULINUMTOXINA to MULTIPLE USE OF SINGLE USE PRODUCT. This represents approximately 2.2% of all 126,795 adverse event reports for this drug.
ONABOTULINUMTOXINA has an overall safety score of 78 out of 100. Patients taking ONABOTULINUMTOXINA who experience multiple use of single use product should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MULTIPLE USE OF SINGLE USE PRODUCT is a less commonly reported adverse event for ONABOTULINUMTOXINA, but still significant enough to appear in the safety profile.
In addition to multiple use of single use product, the following adverse reactions have been reported for ONABOTULINUMTOXINA:
MULTIPLE USE OF SINGLE USE PRODUCT has been reported as an adverse event in 2,798 FDA reports for ONABOTULINUMTOXINA. This does not prove causation, but indicates an association observed in post-market surveillance data.
MULTIPLE USE OF SINGLE USE PRODUCT accounts for approximately 2.2% of all adverse event reports for ONABOTULINUMTOXINA, making it a notable side effect.
If you experience multiple use of single use product while taking ONABOTULINUMTOXINA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.